Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Commentary|Podcasts|January 11, 2024
Dr. Schwen on focal therapies for prostate cancer
Author(s)Cleveland Clinic
Advertisement
On an episode of Cleveland Clinic’s Cancer Advances podcast, host Dale Shepard, MD, PhD, talked with Zeyad Schwen, MD, about the use of focal therapy to treat patients with localized prostate cancer.
Schwen, who is a urologic oncologist at Cleveland Clinic, covers these topics:
- The difference between traditional treatments and focal therapies
- Factors that make a patient a good candidate for focal therapy
- Focal procedures, including Nanoknife, high-intensity focused ultrasound and cryotherapy
- Risk of recurrence and salvage therapies
- Clinical trials devoted to focal therapies
Advertisement
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5